Pneumocystis carinii is the causative agent of P. carinii pneumonia (PCP),
an opportunistic infection associated with AIDS and other immunosuppressed
conditions. Although polyamine metabolism of this fungus has been shown to
be a chemotherapeutic target, this metabolism has not been thoroughly inves
tigated. Reported here is the effect of one polyamine analogue, N,N'-bis(3-
[(phenylmethyl)amino]propyl)(BBS), on P, carinii. BBS inhibits the growth o
f P, carinii in culture, but at concentrations higher than those required t
o inhibit the growth of other pathogens, However, BBS is at least as active
in an animal model of PCP as in other models of diseases studied. BBS caus
es some reduction in P, carinii polyamine content and polyamine biosyntheti
c enzyme activities, but the effect is less than that observed with other p
athogens and very much less than the effect of the polyamine biosynthesis i
nhibitor DL-alpha-difluoromethylornithine. BBS enters P, carinii cells via
a polyamine transporter, unlike all other cells that have been studied. P,
carinii cells do not remove the benzyl groups of BBS, as is reported for ma
mmalian cells. The most likely mode of action is displacement of natural po
lyamines, Overall, the activity of BBS provides further evidence that polya
mines and polyamine metabolism are rational targets for the development of
drugs to treat PCP, Because the details of BBS-P, carinii interaction diffe
r from those of other cells studied, polyamine analogues may provide a high
ly specific treatment for PCP.